Muthiah Vaduganathan, MD
Cardiovascular Disease · Boston, MANPI 1023370467
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $675,540 of the $971,736 with a category attached, or 69.5%. It is spread thinly across 35 manufacturers, the largest accounting for just 12.4%. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 480 payments — averaging $2024.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$120K
- Bayer$94K
- Lexicon Pharmaceuticals, Inc.$93K
- Boehringer Ingelheim$73K
- Amgen$68K
- Boehringer Ingelheim International GmbH$64K
- plus $460K from 29 others
Across 13 payments — averaging $44,411 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics International Ltd$417K
- American Regent$143K
- Bayer$13K
- Novartis$2K
- Sanofi-aventis U.S. LLC$1K
- Boehringer Ingelheim International GmbH$80
What the payments were for
- Consulting fees$675,54070%
- Speaking & faculty fees$107,17611%
- Grants$54,0006%
- Travel & lodging$125,61013%
- Food & beverage$9,4091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 81 | $120,366 |
| Bayer | 77 | $94,370 |
| Lexicon Pharmaceuticals, Inc. | 12 | $92,504 |
| Boehringer Ingelheim | 51 | $72,760 |
| Amgen | 32 | $68,064 |
| Boehringer Ingelheim International GmbH | 25 | $63,617 |
| Occlutech US LLC | 1 | $54,000 |
| Roche Diagnostics International Ltd | 18 | $50,885 |
| Novo Nordisk AS | 11 | $46,799 |
| Novo Nordisk | 17 | $38,090 |
| Eli Lilly | 16 | $38,048 |
| Astrazeneca UK Limited | 33 | $34,383 |
| Pharmacosmos Therapeutics Inc. | 4 | $25,409 |
| Sanofi-aventis U.S. LLC | 6 | $21,955 |
| American Regent | 7 | $20,844 |
| Lilly USA, LLC | 7 | $20,400 |
| Merck | 22 | $17,731 |
| Recordati_rare_diseases_inc. | 7 | $15,314 |
| Esperion Therapeutics, Inc. | 6 | $13,907 |
| E.r. Squibb & Sons, L.L.C. | 8 | $11,144 |
| Chiesi USA, Inc. | 2 | $8,797 |
| Novartis | 9 | $8,511 |
| Astrazeneca AB | 4 | $7,804 |
| Alnylam Pharmaceuticals Inc. | 4 | $5,367 |
| Baxter Healthcare | 2 | $4,971 |
| Roche Diagnostics Corporation | 2 | $4,839 |
| Vifor Pharma, Inc. | 7 | $3,721 |
| Idorsia Pharmaceuticals US Inc | 1 | $3,540 |
| Boehringer Ingelheim Del Ecuador Cia. Ltda. | 1 | $2,320 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $805 |
| Impulse Dynamics (USA) Inc. | 2 | $165 |
| Sandoz | 1 | $125 |
| Edwards Lifesciences | 1 | $91 |
| Endotronix, Inc. | 1 | $50 |
| Boston Scientific | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$63,236
- JARDIANCE$57,977
- FARXIGA$25,577
- Monoferric$25,409
- MULTAQ$21,896
- INJECTAFER$20,754
- NEXLIZET$13,860
- NEXLETOL$13,860
- OSILODROSTAT$10,642
- Non-Covered$10,038
- BREZTRI$9,151
- KENGREAL$8,797
- LEQVIO$7,856
- Fluid Systems - Non Prod Related$4,971
- Elecsys Troponin T Gen 5 STAT$4,870
- Ozempic$4,500
- Tryvio$3,540
- Veltassa$3,496
- MOUNJARO$2,800
- Repatha$2,750
How this compares
$971,736 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 84 | $99,380 |
| JardianceEmpagliflozin | 62 | $88,230 |
| FarxigaDapagliflozin Propanediol | 37 | $45,471 |
| EntrestoSacubitril/Valsartan | 22 | $23,806 |
| Sildenafil Citrate | 11 | $8,088 |
| Metoprolol Succinate | 193 | $3,022 |
| Atorvastatin Calcium | 139 | $1,927 |
| Rosuvastatin Calcium | 55 | $1,318 |
| Ezetimibe | 49 | $1,262 |
| Spironolactone | 63 | $704 |
| Amlodipine Besylate | 62 | $640 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $598 |
| Chlorthalidone | 21 | $575 |
| Losartan Potassium | 29 | $488 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 18 | $404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $72,760 | $88,23062 claims |
| AstraZenecaFarxiga | $120,366 | $45,47137 claims |
| NovartisEntresto | $8,511 | $23,80622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
- Jorge PlutzkyBoston$528K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.